By outsourcing high-end processes that demand advanced analytical and technical skills, biopharm companies are reaping substantial savings.
Hazel Aranha
Advertisement
Articles by Hazel Aranha
The biotechnology and pharmaceutical industries have some overriding concerns, namely regulatory and compliance issues, insufficient manufacturing capacity, and the economic challenges of producing niche drugs and therapies.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
5